These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24413343)

  • 1. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.
    Goldfien RD; Ng MS; Yip G; Hwe A; Jacobson A; Pressman A; Avins AL
    BMJ Open; 2014 Jan; 4(1):e003627. PubMed ID: 24413343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    Singh JA; Yang S; Saag KG
    J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
    J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.
    Goldfien R; Pressman A; Jacobson A; Ng M; Avins A
    Perm J; 2016; 20(3):15-234. PubMed ID: 27352414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
    Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.